Drug Type Gene editing |
Synonyms NTLA 1001, NTLA-1001, NTLA1001 |
Target |
Action modulators |
Mechanism TTR modulators(Transthyretin modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Amyloidosis | Preclinical | United States | 15 Jan 2021 |





